News | October 04, 2012

Multi-Leaf Collimator Increases Accuracy, Reduces Radio Therapy Dose at James Cook University Hospital

October 4, 2012 — Less than three months after beginning clinical use of their Elekta Agility 160-leaf multi-leaf collimator (MLC), physicians at The James Cook University Hospital in Middlesbrough, England, have achieved another benchmark – their first use of Agility to deliver radiation therapy employing Elekta's volumetric modulated arc therapy (VMAT). The ability to accelerate both beam shaping and beam delivery with Agility and VMAT cut 57 seconds off the beam delivery time for the first patient, a 61-year-old male with prostate cancer.

Using twice the number of leaves typical of many standard MLCs, Agility precisely sculpts delivered radiation to the distinctive contours of the tumor, while reducing the risk of exposure to healthy normal tissues. Agility also includes ultra-fast leaf movements – twice as fast as other MLCs commonly used in the industry. Agility complements rapid beam delivery techniques, such as VMAT, in which single or multiple radiation beams sweep in one or more uninterrupted arcs around the patient, reducing treatment times significantly.

On Aug. 8, the patient received his first treatment fraction, a single 200-degree VMAT arc, which took just 83 seconds to deliver. In comparison, a three-field 3-D conformal treatment would have taken 140 seconds (2:20 minutes) to deliver, demonstrating a 40.7 percent reduction in beam delivery time with Agility/VMAT. When factoring in image guidance, the total treatment timesavings with Agility/VMAT was 72 seconds (1:12 minutes).

"This was our first experience with VMAT and it went very well," said Christopher Walker, head of radiotherapy physics at The James Cook University Hospital. "The treatment speed not only reduces the likelihood that the patient will move and that the internal organs will shift position, but it also contributes to faster patient throughput, which is key. With Agility/VMAT we expect to be able to treat five patients per hour."

A new version of Monaco (v 3.20) was used to plan the first Agility/VMAT case. "We used PIVOTAL trial dose constraints, achieving good coverage of the target and optimal sparing of the rectum and bladder," Walker said. "It was a significant improvement over our previous 3-D conformal planning."

The image guidance technology on their Elekta Synergy treatment system also was critical for ensuring accuracy. "We wouldn't have done the treatment without the cone beam CT [computed tomography] on the Synergy system," he added. "Through image guidance we identified movement of the target volume before treatment delivery on the first day, which resulted in us re-planning the patient before subsequent treatments."

With the successful launch of Agility/VMAT at The James Cook University Hospital, clinicians there have begun treating a second prostate patient and a third is on the schedule. "We're now open for business as far as prostate VMAT is concerned," Walker said. "Looking ahead, we will be expanding out to other sites in the body over the next few months."

Agility is not available for sale or distribution in all markets.

For more information:

Related Content

Proton Therapy Lowers Risk of Side Effects Compared to Conventional Radiation
News | Proton Therapy | May 23, 2019
Cancer patients getting proton therapy instead of traditional photon radiation are at a significantly lower risk of...
Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Varian Acquiring Cancer Treatment Services International
News | Radiation Therapy | May 21, 2019
Varian Medical Systems announced it has entered into a definitive agreement to acquire India’s Cancer Treatment...
Videos | Radiation Therapy | May 21, 2019
This is a walk through of the ViewRay MRIdian MRI-guided radiotherapy system installed at ...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
New Method Improves Ability to Measure and Maximize Radiation Therapy Dose
News | Radiation Therapy | May 14, 2019
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime....
Sponsored Content | Videos | Radiation Oncology | May 13, 2019
At ASTRO 2018, Accuray showcased new patient-fi
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
IBA Partnering to Develop Advanced Digital Proton Therapy Technologies in Belgium
News | Proton Therapy | May 10, 2019
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain...